Ignite Creation Date:
2024-05-05 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 9:52 AM
Study NCT ID:
NCT00713687
Status:
WITHDRAWN
Last Update Posted:
2012-08-10
First Post:
2008-07-07
Brief Title:
GemcitabineOxaliplatin and Photodynamic Therapy in Cholangiocarcinoma
Sponsor:
Technical University of Munich
Organization:
Technical University of Munich
Study Overview
Official Title:
Sequential Combination of Chemotherapy With GemcitabineOxaliplatin and Photodynamic Therapy in Advanced Cholangiocarcinoma
Status:
WITHDRAWN
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
recruiting failed
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GemOx-PDT
Brief Summary:
In patients with cholangiocarcinoma therapeutic effects have been reported for GemcitabineOxaliplatin Furthermore photodynamic therapy PDT has significantly improved patients survival in two randomised trials PDT induces tumor necrosis only in an area of few millimetres while tumor parts which are located beyond this area remain untreated An additive effect could result from PDT as a local therapy in combination with systemic chemotherapy
Detailed Description:
Patients entered in the study receive a sequential therapy consisted of photodynamic therapy followed by systemic chemotherapy GemcitabineOxaliplatin 4 weeks later Systemic chemotherapy every 2 weeks is scheduled 9 times in each cycle Thereafter another cycle of PDT followed by chemotherapy is intended
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT-Nr 2008-001560-37 | None | None | None |